OX40L/OX40信号通路对T细胞的影响及其作为特应性皮炎治疗靶点的应用与展望

doi:10.35541/cjd.20240533

Abstract

Abstract: 【Abstract】 Atopic dermatitis （AD） is an inflammatory skin condition caused by multiple factors, mainly characterized by T-cell mediated skin inflammation and disruption of the skin barrier. Tumor necrosis factor receptor superfamily member 4 （OX40） and its ligand （OX40L） serve as important factors in mediating T cell immune responses, contributing to pathogenic T cell proliferation and survival and promoting the secretion of inflammatory cytokines. This signaling pathway is closely associated with systemic and local inflammatory responses. At present, monoclonal antibodies targeting the OX40L/OX40 pathway have demonstrated significant efficacy and long-term improvement in clinical trials for moderate-to-severe AD, and may become important targeted therapeutics for AD in the future.

Key words: Dermatitis, atopic, OX40L/OX40 signaling pathway, T cell, Therapy

Yin Huibin, Li Wei. Effects of the OX40L/OX40 signaling pathway on T cells and its application and prospects as a therapeutic target in atopic dermatitis[J]. Chinese Journal of Dermatology,2026,e20240533. doi:10.35541/cjd.20240533

References ［28］

［1］	中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会. 中国中重度特应性皮炎诊疗临床路径专家共识（2023版）［J］. 中华皮肤科杂志, 2023,56（11）:1000⁃1007. DOI: 10.35541/cjd.20230247.
［2］	Furue M, Furue M. OX40L⁃OX40 signaling in atopic dermatitis［J］. J Clin Med, 2021,10（12）:2578. DOI: 10.3390/jcm10122578.
［3］	Fu N, Xie F, Sun Z, et al. The OX40/OX40L axis regulates T follicular helper cell differentiation: implications for autoimmune diseases［J］. Front Immunol, 2021,12:670637. DOI: 10.3389/fimmu.2021.670637.
［4］	Elsner JS, Carlsson M, Stougaard JK, et al. The OX40 axis is associated with both systemic and local involvement in atopic dermatitis［J］. Acta Derm Venereol, 2020,100（6）:adv00099. DOI: 10.2340/00015555⁃3452.
［5］	中国医师协会皮肤科医师分会, 中华医学会皮肤性病学分会, 中国医疗保健国际交流促进会皮肤医学分会, 等. 特应性皮炎治疗药物应用管理专家共识（2024版）［J］. 中华皮肤科杂志, 2024,57（2）:97⁃108. DOI: 10.35541/cjd.20230358.
［6］	Nakahara T, Kido⁃Nakahara M, Tsuji G, et al. Basics and recent advances in the pathophysiology of atopic dermatitis［J］. J Dermatol, 2021,48（2）:130⁃139. DOI: 10.1111/1346⁃8138.15664.
［7］	Wu Y, Gu C, Wang S, et al. Serum biomarker⁃based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab［J］. Br J Dermatol, 2023,188（5）:649⁃660. DOI: 10. 1093/bjd/ljad032.
［8］	Fu Y, Lin Q, Zhang Z, et al. Therapeutic strategies for the costimulatory molecule OX40 in T⁃cell⁃mediated immunity［J］. Acta Pharm Sin B, 2020,10（3）:414⁃433. DOI: 10.1016/j.apsb. 2019.08.010.
［9］	Gajdasik DW, Gaspal F, Halford EE, et al. Th1 responses in vivo require cell⁃specific provision of OX40L dictated by environmental cues［J］. Nat Commun, 2020,11（1）:3421. DOI: 10.1038/s41467⁃020⁃17293⁃3.
［10］	Murata K, Ishii N, Takano H, et al. Impairment of antigen⁃presenting cell function in mice lacking expression of OX40 ligand［J］. J Exp Med, 2000,191（2）:365⁃374. DOI: 10.1084/jem. 191.2.365.
［11］	Hoshino A, Tanaka Y, Akiba H, et al. Critical role for OX40 ligand in the development of pathogenic Th2 cells in a murine model of asthma［J］. Eur J Immunol, 2003,33（4）:861⁃869. DOI: 10.1002/eji.200323455.
［12］	Yi K, Jo S, Song W, et al. Analysis of single⁃cell transcriptome and surface protein expression in ankylosing spondylitis Identifies OX40⁃positive and glucocorticoid⁃induced tumor necrosis factor receptor⁃positive pathogenic Th17 cells［J］. Arthritis Rheumatol, 2023,75（7）:1176⁃1186. DOI: 10.1002/art. 42476.
［13］	Kumari R, Chakraborty S, Jain R, et al. Inhibiting OX40 restores regulatory T⁃cell function and suppresses inflammation in pulmonary sarcoidosis［J］. Chest, 2021,160（3）:969⁃982. DOI: 10.1016/j.chest.2021.04.032.
［14］	Kuang Z, Jing H, Wu Z, et al. Development and characterization of a novel anti⁃OX40 antibody for potent immune activation［J］. Cancer Immunol Immunother, 2020,69（6）:939⁃950. DOI: 10. 1007/s00262⁃020⁃02501⁃2.
［15］	Fujita T, Ukyo N, Hori T, et al. Functional characterization of OX40 expressed on human CD8+ T cells［J］. Immunol Lett, 2006,106（1）:27⁃33. DOI: 10.1016/j.imlet.2006.04.001.
［16］	Guttman⁃Yassky E, Croft M, Geng B, et al. The role of OX40 ligand/OX40 axis signalling in atopic dermatitis［J］. Br J Dermatol, 2024,191（4）:488⁃496. DOI: 10.1093/bjd/ljae230.
［17］	Seshasayee D, Lee WP, Zhou M, et al. In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation［J］. J Clin Invest, 2007,117（12）:3868⁃3878. DOI: 10.1172/JCI33559.
［18］	Murakami⁃Satsutani N, Ito T, Nakanishi T, et al. IL⁃33 promotes the induction and maintenance of Th2 immune responses by enhancing the function of OX40 ligand［J］. Allergol Int, 2014,63（3）:443⁃455. DOI: 10.2332/allergolint.13⁃OA⁃0672.
［19］	Guttman⁃Yassky E, Pavel AB, Zhou L, et al. GBR 830, an anti⁃OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis［J］. J Allergy Clin Immunol, 2019,144（2）:482⁃493. DOI: 10.1016/j.jaci.2018.11.053.
［20］	Rewerska B, Sher LD, Alpizar S, et al. Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate⁃to⁃severe atopic dermatitis［J］. J Allergy Clin Immunol Glob, 2024,3（1）:100195. DOI: 10.1016/j.jacig.2023.100195.
［21］	Guttman⁃Yassky E, Simpson EL, Reich K, et al. An anti⁃OX40 antibody to treat moderate⁃to⁃severe atopic dermatitis: a multicentre, double⁃blind, placebo⁃controlled phase 2b study［J］. Lancet, 2023,401（10372）:204⁃214. DOI: 10.1016/S0140⁃6736（22）02037⁃2.
［22］	Guttman⁃Yassky E, Simpson E, Esfandiari E, et al. Rocatinlimab: a novel T⁃cell rebalancing therapy targeting the OX40 receptor in atopic dermatitis［J］. Dermatol Ther （Heidelb）, 2025,15（11）:3153⁃3171. DOI: 10.1007/s13555⁃025⁃01492⁃1.
［23］	Weidinger S, Bieber T, Cork MJ, et al. Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti⁃OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase Ⅱa randomized placebo⁃controlled trial［J］. Br J Dermatol, 2023,189（5）:531⁃539. DOI: 10.1093/bjd/ljad240.
［24］	Weidinger S, Blauvelt A, Papp KA, et al. Phase 2b randomized clinical trial of amlitelimab, an anti⁃OX40 ligand antibody, in patients with moderate⁃to⁃severe atopic dermatitis［J］. J Allergy Clin Immunol, 2024:S0091⁃6749（24）01175⁃8. DOI: 10.1016/j.jaci.2024.10.031.
［25］	Bieber T, Katoh N, Simpson EL, et al. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials［J］. J Dermatolog Treat, 2023,34（1）:2161812. DOI: 10.1080/09546634.2022.2161812.
［26］	López⁃Abente J, Bernaldo⁃de⁃Quirós E, Camino M, et al. Immune dysregulation and Th2 polarization are associated with atopic dermatitis in heart⁃transplant children: a delicate balance between risk of rejection or atopic symptoms［J］. Am J Transplant, 2019,19（5）:1536⁃1544. DOI: 10.1111/ajt.15245.
［27］	Xiao X, Gong W, Demirci G, et al. New insights on OX40 in the control of T cell immunity and immune tolerance in vivo［J］. J Immunol, 2012,188（2）:892⁃901. DOI: 10.4049/jimmunol.110 1373.
［28］	Saghari M, Gal P, Gilbert S, et al. OX40L inhibition suppresses KLH⁃driven immune responses in healthy volunteers: a randomized controlled trial demonstrating proof⁃of⁃pharmacology for KY1005［J］. Clin Pharmacol Ther, 2022,111（5）:1121⁃1132. DOI: 10.1002/cpt.2539.

[1]	Pediatric Dermatology Group, Chinese Society of Dermatology, Dermatology Group, Chinese Pediatric Society, Chinese Medical Association, Pediatric Group, Chinese Association of Rehabilitation Dermatology, Atopic Dermatitis Group, Chinese Association of Rehabilitation Dermatology, Pediatric Dermatology Group, China Dermatologist Association, Dermatology Group, the Society of Pediatrics, Chinese Medical Doctor Association. Chinese consensus on the prevention, treatment, and management of atopic dermatitis in children（2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(6): 487-504.
[2]	Sun Songpeng, Long Junhong, Cao Bo, Xu Yue, Zhang Xiang′an, Cao Hui, Xie Jun, Gui Ping, Sun Xiaojun, Zhang Bo, Xu Zhijie, Li Jin′an, Wang Zhigang, Wu Wei, Yang Huiju, Wei Ping, Liu Congcong, Shen Qingbo, Yu Fan, Chu Hongchuan, Zhou Yangyang, Liu Jiaxin, Liu Yan, Huo Xingxiao, Chen Hang, Jing Tao, Gao Jing, Wang Yanxun, Wang Rui, Li Zhenyu, Zhang Shuxin. Efficacy and safety of Fuzhiqing ointment versus triamcinolone acetonide and econazole nitrate cream in the treatment of chronic perianal eczema: a multicenter, randomized, double-blind, controlled, equivalence trial [J]. Chinese Journal of Dermatology, 2026, 59(6): 564-570.
[3]	Xu Zhuohong, Zhou Huan, Hu Yu, Gu Heng. Balneotherapy in skin diseases [J]. Chinese Journal of Dermatology, 2026, 59(5): 482-485.
[4]	Chinese Association of Rehabilitation Dermatology, Combination of Traditional and Western Medicine Dermatology. Expert consensus on the diagnosis, treatment and rehabilitation of psoriasis in the elderly （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(5): 407-418.
[5]	Pediatric Dermatology Group, Professional Committee of Pediatric Allergy, China Maternal and Child Health Association. Chinese expert consensus on the diagnosis and management of pediatric anogenital lichen sclerosus （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(5): 396-406.
[6]	Sun Zijun, Ai Fangting, Yao Chunxia, Miao Guoying, Zhang Li. Effects and action mechanisms of Poria cocos and its active component pachymic acid on atopic dermatitis-related inflammatory responses: a study based on network pharmacology analysis and HaCaT cell experiments [J]. Chinese Journal of Dermatology, 2026, 59(5): 443-454.
[7]	Zhang Xiaoxu, Luo Suju. Efficacy and safety of upadacitinib in the treatment of six cases of palmoplantar pustulosis [J]. Chinese Journal of Dermatology, 2026, 59(5): 459-463.
[8]	Chen Xue, Zhang Jianzhong. Chronic hand eczema: epidemiology, disease burden, pathogenesis, and management [J]. Chinese Journal of Dermatology, 2026, 59(4): 327-332.
[9]	Huang Chinin, Ma Yinchao, Wang Ziyuan, Lu Xilin, Qi Yingting, Liu Ziyan, Men Yuehua, Chu Ming, Zhang Chunlei. Effects of berberine ointment on skin inflammation and microbiota in an atopic dermatitis-like mouse model [J]. Chinese Journal of Dermatology, 2026, 59(4): 353-360.
[10]	Group on Children, Chinese Society of Dermatology, Pediatric Dermatology Group, Chinese Association of Rehabilitation Dermatology, Pediatric Dermatology Group, China Dermatologist Association, External Therapy Group, Professional Committee for Children's Health and Drug Research, China Association of Traditional Chinese Medicine, Dermatology Group, China Pediatrician Association. Expert consensus on the diagnosis and treatment of pediatric alopecia areata in China （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(4): 291-303.
[11]	Tan Yaxin, Zhi Juan, Zhao Jiaojiao, Lei Jin, Liu Juan. A half-face controlled study on the treatment of facial atrophic scars with fractional laser and acupuncture combined with negative pressure suction [J]. Chinese Journal of Dermatology, 2026, 59(4): 361-365.
[12]	Yang Yuan, Deng Danqi. Early diagnosis and treatment of psoriatic arthritis [J]. Chinese Journal of Dermatology, 2026, 0(3): 20240376-e20240376.
[13]	Yang Wanqing, Chen Nuoran, Meng Xiaoqi, Liu Tingwei, Xu Yang. Application of focused ultrasound in dermatology beyond the anti?aging aspects [J]. Chinese Journal of Dermatology, 2026, 0(3): 20240433-e20240433.
[14]	Zeng Wanxin, Wen Xiang. Photoelectric therapy for hypertrophic scars [J]. Chinese Journal of Dermatology, 2026, 59(3): 269-273.
[15]	Xia Zhikuan, Ge Ge. Laser therapy for vitiligo: clinical applications and prospects [J]. Chinese Journal of Dermatology, 2026, 59(3): 213-217.

Effects of the OX40L/OX40 signaling pathway on T cells and its application and prospects as a therapeutic target in atopic dermatitis

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［28］

Related Articles 15

Metrics

Comments

Recommended 10